**Online supplementary Table 1.** Prevalence and performance of composite scores calculated using alternative wordings of PGA

|  |  |  |  |
| --- | --- | --- | --- |
| Score calculated using alternative PGA | Remission: prevalence (Se/Sp against patient question) | Low disease activity: prevalence (Se/Sp against patient question) | Remission OR Low disease activity: prevalence (Se/Sp against patient questions) |
| DAPSA – joints PGA | 15.9% (44.3/91.9) | 42.7% (61.6/71.7) | 56.6% (73.1/74.6) |
| VLDA/MDA – joints PGA | 12.4% (36.4/94.1) | 24.7% (33.9/82.2) | 37.1% (50.3/ 88.0) |
| DAPSA – skin PGA | 18.3% (38.6/86.0) | 44.1% (56.1/63.9) | 59.3% (75.7/70.4) |
| VLDA/MDA - skin PGA | 10.0% (29.5/94.1) | 30.6% (41.7/74.8) | 41.7% (56.3/84.5) |

The joints PGA and skin PGA were formulated as follows: Considering all the ways your joints have affected you during the last week, circle the number that best describes how you have been doing; and Considering all the ways psoriasis (skin disease) has affected you during the last week, circle the number that best describes how you have been doing.

Sensitivity (Se) is defined as N patients in the status by the score/ N patients in the status according to the patient-defined anchor status. Specificity (Sp) is defined as N patients NOT in the status by the score/ N patients NOT in the status according to the patients-defined anchor status.